Latest AEpiA news

Abstract submission deadline extended

Abstract submission deadline extended

to Tuesday 1st August

7th Australian Epigenetics Conference

29 October – 1 November 2017

Brisbane

Discover the epigenetic innovations of the future. Learn, collaborate and be inspired. Join us in Brisbane to find out about the rapidly moving field of epigenetics and its implications in disease progression and therapy.

 

This is your chance to submit abstracts on the following conference themes:

  • Epigenetic therapies and biomarkers
  • Development and inheritance
  • Epigenetic mechanisms
  • Functional epigenomics
  • Epigenetics and disease
  • Epitranscriptomics

Abstracts are to be a maximum of 300 words (text only) and you can submit as an oral or poster presentation.

To submit your abstract, please click the Submit Abstract button below.

Thank you to our sponsors…

Save the date – EPIGENETICS 2017

Save the Date!

7th Australian Epigenetics Conference

29 October – 1 November 2017

Brisbane

Mark the date in your diary and join us at the Hotel Grand Chancellor in Brisbane for the 7th Epigenetics Australian Scientific Conference.

Discover the epigenetic innovations of the future. Learn, collaborate and be inspired. Join us in Brisbane to find out about the rapidly moving field of epigenetics and its implications in disease progression and therapy.

Themes include:

  • Epigenetic Therapies and Biomarkers
  • Development and Inheritance
  • Epigenetic Mechanisms
  • Functional Epigenomics
  • Epigenetics and Disease
Registrations and call for abstracts will be opening in early April 2017.

For further enquires please do not hesitate call the Conference Secretariat on 07 3368 2422 or email epi@yrd.com.au

 

PhD Opportunities – Hunter Medical Research Institute

PhD Opportunities – DNA Methylation Heterogeneity in Cancer

Cancer cells within a single tumour can differ in clinically important properties such as their ability to initiate metastasis or survive therapy, and a thorough understanding of the molecular characteristics underlying this heterogeneity will have important implications for cancer treatment. DNA methylation is dynamically regulated during development and globally dysregulated in many cancer types, yet little is known about the heterogeneity of this epigenetic modification in cancer.

Recently developed single-cell sequencing technologies have allowed DNA methylation heterogeneity to be studied in unprecedented detail. Based in the Hunter Medical Research Institute, the laboratory of Dr Heather Lee will apply these methods to investigate DNA methylation heterogeneity and dynamics in cancer. Two opportunities exist for talented molecular biologists to undertake a PhD project in this newly established research team.

Specific aims that could be addressed are:

1. To determine the relationship between DNA methylation plasticity and cellular plasticity during epithelial to mesenchymal transition and metastasis.

2. To investigate the contribution of DNA methylation heterogeneity to the heterogeneous response of cancer cells to therapy.

3. To identify targets for DNA methylation biomarker development based on molecular characterisation of circulating tumour cells, metastasis initiating cells or putative cancer stem cells.

These research projects will involve collaboration with scientists at the Garvan-Weizmann Centre for Cellular Genomics at the Kinghorn Cancer Centre, Sydney. Depending on the specific aims of the research project, the candidate will develop technical skills in cell culture, in vitro assays of cancer biology, in vivo models of cancer, DNA methylation analysis, single-cell sequencing technologies and bioinformatics.

Applications are open to international and domestic candidates.

Interested applicants are advised to email a curriculum vitae and cover letter to the address below.

Email: sbs-rsu@newcastle.edu.au

Applications are open until suitable candidates are found.